Status:
COMPLETED
Fenofibrate in Type 2 Diabetes
Lead Sponsor:
Medical University of South Carolina
Conditions:
Diabetes Mellitus, Type II
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Diabetic complications affecting the eyes, kidneys, and nerves are difficult to arrest once in progress. Recent evidence that fenofibrate confers a robust yet unexpected benefit in diabetic retinopath...
Eligibility Criteria
Inclusion
- Type 2 diabetes of at least one year's duration; stable glycemic control (no more than 1.0% change in HbA1c in the previous six months, but no limit on HbA1c)
- Triglycerides \>150 mg/dL (in the previous six months)
Exclusion
- Previous use of Fenofibrate or other fibrates
- Pregnancy
- Active malignancy
- Recent cardiac event or congestive heart failure
- Active liver disease
- Significant renal impairment (serum creatinine \> 2mg/dl)
Key Trial Info
Start Date :
February 4 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 4 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03829514
Start Date
February 4 2019
End Date
March 4 2020
Last Update
October 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of South Carolina
Charleston, South Carolina, United States, 29425